RG
SLDB icon

Redmile Group’s Solid Biosciences SLDB Stock Holding History

Redmile Group’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.5M Sell
1,948,695
-63,200
-3% -$479K 1.31% 17
2026
Q1 		$14.5M Buy
2,011,895
+151,353
+8% +$973K 0.96% 18
2025
Q4 		$10.5M Sell
1,860,542
-38,800
-2% -$210K 0.77% 22
2025
Q3 		$11.7M Sell
1,899,342
-16,584
-0.9% -$97K 1.14% 21
2025
Q2 		$9.33M Sell
1,915,926
-103,245
-5% -$365K 0.99% 23
2025
Q1 		$7.47M Buy
2,019,171
+1,403,925
+228% +$6.01M 0.71% 29
2024
Q4 		$2.46M Buy
+615,246
New +$3.38M 0.17% 53

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Redmile Group's SLDB Position: Q2 2026 in Review

Redmile Group reduced its Solid Biosciences (SLDB) stake by 3.1% in Q2 2026, selling an estimated $479K and leaving 1,948,695 shares worth $19.5M. The position accounts for 1.31% of the portfolio, ranked #17.

Redmile Group first reported a position in SLDB in Q4 2024 and has held it in 7 quarters since. 156 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Redmile Group held 1,948,695 shares of Solid Biosciences worth $19.5M as of Q2 2026.
  • Redmile Group sold 63,200 Solid Biosciences shares in Q2 2026, an estimated $479K.
  • Solid Biosciences made up 1.31% of Redmile Group's portfolio in Q2 2026, its #17 holding.
  • Redmile Group first reported a position in Solid Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 156 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Redmile Group's 13F filing for Q2 2026, filed 14 Aug 2026.